Expansion of quiescent lung adenocarcinoma CD8(+) T cells by MUC1-8-mer peptide-T2 cell-β2 microglobulin complexes

Adoptive immunotherapy requires the isolation of CD8(+) T cells specific for tumor-associated antigens, their expansion in vitro and their transfusion to the patient to mediate a therapeutic effect. MUC1 is an important adenocarcinoma antigen immunogenic for T cells. The MUC1-derived SAPDTRPA (MUC1-8-mer) peptide is a potent epitope recognized by CD8(+) T cells in murine models. Likewise, the T2 cell line has been used as an antigen-presenting cell to activate CD8(+) T cells, but so far MUC1 has not been assessed in this context. We evaluated whether the MUC1-8-mer peptide can be presented by T2 cells to expand CD25(+)CD8(+) T cells isolated from HLA-A2(+) lung adenocarcinoma patients with stage III or IV tumors. The results showed that MUC1-8-mer peptide-loaded T2 cells activated CD8(+) T cells from cancer HLA-A2(+) patients when anti-CD2, anti-CD28 antibodies and IL-2 were added. The percentage of CD25(+)CD8(+) T cells was 3-fold higher than those in the non-stimulated cells (P=0.018). HLA-A2(+) patient cells showed a significant difference (2.3-fold higher) in activation status than HLA-A2(+) healthy control cells (P=0.04). Moreover, 77.6% of MUC1-8-mer peptide-specific CD8(+) T cells proliferated following a second stimulation with MUC1-8-mer peptide-loaded T2 cells after 10 days of cell culture. There were significant differences in the percentage of basal CD25(+)CD8(+) T cells in relation to the cancer stage; this difference disappeared after MUC1-8-mer peptide stimulation. In conclusion, expansion of CD25(+)CD8(+) T cells by MUC1-8 peptide-loaded T2 cells plus costimulatory signals via CD2, CD28 and IL-2 can be useful in adoptive immunotherapy.